NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
Clinical Trials
29 trialsNCT05818683 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06353386 2026-03-24
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT06890832 2025-03-24
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
Jina Pharmaceuticals Inc.
Phase 2 Not yet recruiting
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT01447225 2016-09-14
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Completed
NCT01751308 2016-08-12
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Sanofi
Phase 1/2 Completed
NCT01649635 2016-07-06
PROSPECTA
Sanofi
Phase 4 Completed
NCT01140607 2015-07-21
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Sanofi
Phase 1 Completed
NCT01500720 2015-04-13
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT01324583 2015-01-07
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sanofi
Phase 1 Completed
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed
NCT01001221 2013-09-11
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Sanofi
Phase 1/2 Terminated
NCT00925743 2013-05-16
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
Sanofi
Phase 1 Completed
NCT01755390 2012-12-24
A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01087021 2011-12-16
QT-Cab
Sanofi
Phase 1 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed